The 13 analysts offering 12-month price forecasts for Ascendis Pharma A/S have a median target of 142.85, with a high estimate of 198.28 and a low estimate of 110.90. The median estimate represents a +32.41% increase from the last price of 107.88.
The current consensus among 14 polled investment analysts is to Buy stock in Ascendis Pharma A/S. This rating has held steady since October, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$2.51
Reporting Date Apr 03
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.